120 related articles for article (PubMed ID: 33648884)
1. Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study.
Meckstroth S; Wang R; Ma X; Podoltsev N
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e551-e558. PubMed ID: 33648884
[TBL] [Abstract][Full Text] [Related]
2. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis.
Mascarenhas J; Mehra M; He J; Potluri R; Loefgren C
J Med Econ; 2020 Jul; 23(7):721-727. PubMed ID: 32159402
[No Abstract] [Full Text] [Related]
3. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
Verstovsek S; Parasuraman S; Yu J; Shah A; Kumar S; Xi A; Harrison C
Ann Hematol; 2022 Jan; 101(1):131-137. PubMed ID: 34625831
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs.
Gerds AT; Yu J; Shah A; Xi A; Kumar S; Scherber R; Parasuraman S
J Med Econ; 2023; 26(1):843-849. PubMed ID: 37294103
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; VillivĂ N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
[TBL] [Abstract][Full Text] [Related]
6. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; CrisĂ E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.
Copher R; Kee A; Gerds A
Oncologist; 2022 Mar; 27(3):228-235. PubMed ID: 35274711
[TBL] [Abstract][Full Text] [Related]
8. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
Thomas JW; Jamy O; Shah MV; Vachhani P; Go RS; Goyal G
Leuk Res; 2022 Jan; 112():106770. PubMed ID: 34920340
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.
Ellis MH; Koren-Michowitz M; Lavi N; Vannucchi AM; Mesa R; Harrison CN
Leuk Res; 2017 Oct; 61():6-9. PubMed ID: 28843161
[TBL] [Abstract][Full Text] [Related]
10. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.
Kuykendall AT; Shah S; Talati C; Al Ali N; Sweet K; Padron E; Sallman DA; Lancet JE; List AF; Zuckerman KS; Komrokji RS
Ann Hematol; 2018 Mar; 97(3):435-441. PubMed ID: 29189896
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
12. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.
Kuykendall AT; Talati C; Al Ali N; Sweet K; Padron E; Sallman DA; Lancet JE; List AF; Zuckerman KS; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e45-e53. PubMed ID: 28869184
[TBL] [Abstract][Full Text] [Related]
13. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
14. Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.
Oritani K; Ohishi K; Okamoto S; Kirito K; Komatsu N; Tauchi T; Handa H; Saito S; Takenaka K; Shimoda K; Okada H; Amagasaki T; Wakase S; Shimozuma K; Akashi K
Curr Med Res Opin; 2018 Mar; 34(3):531-537. PubMed ID: 29224367
[TBL] [Abstract][Full Text] [Related]
15. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
Verstovsek S; Gotlib J; Gupta V; Atallah E; Mascarenhas J; Quintas-Cardama A; Sun W; Sarlis NJ; Sandor V; Levy RS; Kantarjian HM; Mesa RA
Onco Targets Ther; 2013; 7():13-21. PubMed ID: 24368888
[TBL] [Abstract][Full Text] [Related]
16. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
17. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
[TBL] [Abstract][Full Text] [Related]
18. Clarifying the use of ruxolitinib in patients with myelofibrosis.
Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
[TBL] [Abstract][Full Text] [Related]
19. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.
Kehl KL; Hassett MJ; Schrag D
Cancer Med; 2020 Mar; 9(6):2019-2029. PubMed ID: 31989786
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]